LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering

November 06, 2025 | Last Trade: US$ 0 0.00 0.00

REDWOOD CITY, Calif., Nov. 6, 2025 /PRNewswire/ -- Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a leading law firm in technology and life sciences transactions, represented long-time client BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company on a mission to make powerful and accessible genetic tests available to all, in its upsized initial public offering of 4.6 million shares of Class A common stock at a price to the public of $60 per share, generating approximately $273.1 million in aggregate gross proceeds. The shares began trading on the Nasdaq Global Select Market on November 6, 2025, and the offering is expected to close on November 7, 2025.

Gunderson Dettmer represented BillionToOne through multiple major financing rounds, from its Series A to late-stage equity and debt private rounds. Gunderson's strategic counsel supported BillionToOne from early-stage funding to public markets entry, navigating a dynamic and complex capital markets environment including the current government shutdown.

J.P. Morgan, Piper Sandler, Jefferies and William Blair are acting as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG are also acting as book-running managers for the offering.

The Gunderson deal team included corporate partner Nick Harley, Public Companies/Public Offerings partners Andrew Thorpe and Alexa Belonick, Public Companies/Public Offerings associates Elena Vespoli and Michael Tiab, corporate associates Jenny Whalen-Ball and Megan Wiener, executive compensation partner Michael Richman and associate Erik Ward, and senior paralegals Scott Paraker and Doug Ikegami.

About Gunderson Dettmer

Gunderson Dettmer is the preeminent international law firm with an exclusive focus on the innovation economy. The firm serves market-leading venture capital and growth equity investors and pioneering companies through inception, growth and maturity, as well as groundbreaking public companies that result from the global venture capital ecosystem. The firm's clear-cut focus and well-honed technical skill enables an accelerated pace and unmatched efficiency, delivering best-in-class value at each phase of a client's business.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page